Please login to the form below

Not currently logged in
Email:
Password:

liver transplant

This page shows the latest liver transplant news and features for those working in and with pharma, biotech and healthcare.

Gilead lead NASH drug flunks phase 3 test

Gilead lead NASH drug flunks phase 3 test

It causes fatty build-up and fibrosis in the liver, in serious cases leading to cirrhosis and the need for a liver transplant. ... In phase 2 testing, VK2809 was shown to significantly reduce fat in the liver – another key pathology in NASH – and

Latest news

  • Merck’s backing of NGM Bio yields NASH drug deal Merck’s backing of NGM Bio yields NASH drug deal

    It causes fatty build-up and fibrosis in the liver, sometimes leading to cirrhosis and the need for a liver transplant, and so far has no approved treatments with some analysts ... levels of fat in the liver and improve metabolic measures such as blood

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    It is characterised by a build-up of fat that can lead to liver fibrosis, cirrhosis and - in some patients - the need for a liver transplant. ... Inflammation is considered to be a trigger for the liver damage that characterises the disease.

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    transplant. In the NASH study, 39% of patients taking a high dose of the drug once daily for 24 weeks experienced at least a 30% reduction in liver fat, compared to ... Once again, in that study the FXR agonist was associated with a significant

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Non-Alcoholic Steatohepatitis ( NASH) has been ‘the next big thing’ for a few years now, with many big pharma licensing deals for new treatments for the fatty liver disease, and racing ... Characterised by a build-up of fat that can lead to fibrosis,

  • Viking throws down gauntlet in NASH battle Viking throws down gauntlet in NASH battle

    The build-up of liver fat can lead to fibrosis, cirrhosis and - in some patients - the need for a liver transplant. ... weeks’ treatment, tackling one of the main biomarkers for NASH and other forms of non-alcoholic fatty liver disease (NAFLD), and

More from news
Approximately 3 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics